Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Quick facts
Marketed products
Phase 3 pipeline
- Allogenic MSCs · Regenerative Medicine / Immunology
Allogeneic mesenchymal stem cells (MSCs) exert immunomodulatory and regenerative effects by secreting anti-inflammatory cytokines and promoting tissue repair. - Autologous MSCs · Regenerative Medicine / Orthopedics
Autologous mesenchymal stem cells (MSCs) are harvested from the patient's own bone marrow or adipose tissue and administered to promote tissue repair and modulate immune responses.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León portfolio CI brief
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León pipeline updates RSS
Frequently asked questions about Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
What are Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León's marketed drugs?
Top marketed products include VERDYE powder for solution for injection 25 mg.
What is Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León's pipeline?
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Allogenic MSCs, Autologous MSCs.